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Abstract
“Candidatus Mycoplasma turicensis” infects felids. The pathogenesis of “Candidatus M. turicensis” chronic infection is
poorly understood. The goals of the present study were to (1) induce reactivation of the infection in chronic carrier
cats by attempted immunosuppression, (2) identify potential tissue sequestration using real-time TaqMan
® PCR and
(3) monitor the humoral immune response by DnaK enzyme-linked immunosorbent assay (ELISA). Ten specified
pathogen-free cats that had ostensibly recovered from experimental “Candidatus M. turicensis” infection were used:
five cats (group 1) received high dose methylprednisolone (attempted immunosuppression), while five cats served
as untreated controls (group 2). Besides weekly blood samples, tissue samples were collected from bone marrow,
kidney, liver and salivary glands at selected time points. The cats in group 1 had significantly lower lymphocyte
counts and higher blood glucose levels after methylprednisolone administration than the controls. After
methylprednisolone administration one blood and three tissue samples from cats in group 1 tested PCR-positive;
before the administration, only one sample was positive. All other samples tested PCR-negative. All cats stayed
seropositive; the antibody levels of the cats in group 1 showed a significant transient decrease after
methylprednisolone administration. This is the first study to report the presence of “Candidatus M. turicensis” in
tissues of chronically infected cats and the persistence of anti-feline hemoplasma antibodies in the absence of
detectable bacteremia. Methylprednisolone administration did not lead to a significant reactivation of the infection.
Our results enhance the knowledge of “Candidatus M. turicensis” infection pathogenesis and are clinically relevant
to the prognosis of hemoplasma-infected cats.
Introduction
Hemotropic mycoplasmas, also known as hemoplasmas,
are small, uncultivable, cell-wall-free bacteria that attach to
red blood cells. Hemoplasmas are the causative agents of
infectious anemia in many mammalian species. In domestic
cats, three hemoplasma species have been identified, which
differ in their pathogenic potential [1]: Mycoplasma hae-
mofelis (M. haemofelis), “Candidatus M. haemominutum”
and “Candidatus Mycoplasma turicensis” (”Candidatus M.
turicensis”). “Candidatus M. turicensis” was identified in a
Swiss cat with hemolytic anemia [2]. During the acute
phase of the infection, “Candidatus M. turicensis” can
induce mild to moderate anemia in experimentally infected
domestic cats [2-4]. After bacteremia, hemoplasma-
infected cats may become chronic carriers [5]. To date, it is
assumed that infected animals do not completely clear the
“Candidatus M. turicensis” organisms, even after antibiotic
treatment [6-8]. Different studies have suggested a possible
sequestration of feline hemoplasmas in tissues [9-11]. The
dynamics of the chronic phase of hemoplasma infection,
however, are still poorly understood. We hypothesized that
chronically infected cats may be able to reactivate the
infection under particular conditions, such as immunosup-
pression. Chronic carrier cats could subsequently represent
a source of infection for other animals. To date, no data
from long-term follow-up studies of experimental feline
hemoplasma infection have been reported.
Thus, the goals of the present study were to (1) induce
and investigate the reactivation of chronic experimental
“Candidatus M. turicensis” infection, (2) identify poten-
tial sequestration sites prior to and during the attempted
reactivation of the infection in chronic carrier cats and
(3) monitor the humoral immune response throughout
the experiment.
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Animals and experimental design
The present study was conducted with ten specified
pathogen-free (SPF) male castrated cats. They had under-
gone acute experimental “Candidatus M. turicensis” infec-
tion after subcutaneous inoculation of “Candidatus M.
turicensis”-positive blood in a previous experiment [3].
The cats were kept in groups in a confined university facil-
ity under ideal ethological conditions as described [12]. All
of the experiments were performed according to the law
and were officially approved by the veterinary office of the
canton Zurich (TVB 101/2007). At three months after the
experimental “Candidatus M. turicensis” infection, all cats
tested “Candidatus M. turicensis”-negative in the blood
[3] as determined by polymerase chain reaction (PCR).
The cats were assigned to the present study 12 to 17
months after the experimental infection. For this purpose,
the ten cats were divided into two groups of five: group
1 (cats A2, R2, S1, T1 and X4) received methylpredniso-
lone and group 2 (cats A1, R1, S2, T2 and X5) served
as untreated control cats. The cats underwent regular
clinical examination, and their body weights and tempera-
tures were recorded. The cats were monitored for twenty-
two consecutive weeks after methylprednisolone
administration.
Methylprednisolone administration and tissue sample
collection
In an attempt to immunocompromise the cats and
induce the in vivo reactivation of the “Candidatus M.
turicensis” infection, the cats in group 1 received
three times a high dose of methylprednisolone acetate
(10 mg/kg body weight, i.m., Depo-Medrol ad us. vet.,
Pfizer AG, Zurich, Switzerland) in three consecutive
weeks (first injection = day 0, second and third injec-
tion at days 7 and 14, respectively). Ethylenediaminete-
traacetic acid (EDTA)-anticoagulated blood and serum
samples were collected from all ten cats prior to
methylprednisolone administration and weekly there-
after for hematology, PCR analysis, serology and,
where clinically indicated, serum biochemistry. The
samples for PCR and serology were stored at -80°C
within two hours of collection. Complete hemograms
were performed using a Sysmex XT-2000iV (Sysmex
Corporation, Kobe, Japan) [13]. Packed cell volume
(PCV) values between 33-45% were considered to be
within the reference range, and anemia was defined as
a PCV <33%. For the white blood cell differential,
microscopic blood smear evaluation was performed.
Two blood smears were stained with a modified
Wright-stain on an automated staining instrument for
each blood sample (Hema Tek 1000, Bayer AG, Zurich,
Switzerland). Two technicians with more than ten
years of experience in veterinary hematology differen-
tiated independently 100 cells per smear. Blood glucose
concentrations were determined daily to monitor the
potential development of diabetes mellitus induced by
methylprednisolone. These tests were carried out using
the marginal ear vein prick technique using a portable
blood glucose device (Accu-Check Aviva,R o c h eD i a g -
nostic AG, Basel, Switzerland) [14]. The measurements
were stopped 45 days after the first methylpredniso-
lone administration when the glucose values of all cats
were within the reference range (4-9 mmol/L).
Samples from the kidney, liver and salivary glands
were collected by fine needle aspiration (FNA) 14 days
prior to methylprednisolone administration and 1 and
4 weeks after the end of the methylprednisolone admin-
istration (i.e., at days 20 and 42). In addition, saliva
swabs and bone marrow aspirates were collected. Bone
marrow aspirations were performed on the proximal
humerus as described [3]. All fine needle and bone mar-
row aspirations were performed under a short-duration
general anesthetic using a previously described protocol
[3]. Deoxyribonucleic acid (DNA) was either extracted
immediately after the tissue collection, or the samples
were frozen at -80°C within two hours of the collection.
Nucleic acid extractions
The total nucleic acid (TNA) was extracted from 100 μL
EDTA-anticoagulated blood using the MagNaPure LC
Total Nucleic Acid Isolation Kit (Roche Diagnostics, Rotk-
reuz, Switzerland). The TNA was eluted in 100 μL of elu-
tion buffer and stored at -80°C until PCR was performed.
Nucleic acid was extracted from tissue samples using the
DNA Micro kit (Qiagen, Hombrechtikon, Switzerland).
Saliva swabs and bone marrow samples were extracted
using the DNA blood and tissue kit (Qiagen) according to
the manufacturer’s instructions. The DNA was eluted into
100 μL buffer AE and stored at -80°C until use. During all
extractions, negative controls consisting of 200 μLo f
phosphate-buffered saline were concurrently prepared
with each batch of samples to monitor for cross-
contamination.
Quantitative TaqMan
® real-time PCR assays
The tissue samples were analyzed using a TaqMan
®
real-time PCR amplifying glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) pseudogene [15] to test for
the presence of amplifiable DNA and the absence of sig-
nificant PCR inhibitors as previously described [16].
Only samples with more than 5 000 copies of GAPDH
per reaction were considered to be sufficient, and the
extraction was repeated for samples with insufficient
copies. The “Candidatus M. turicensis” loads were
quantified in all blood and tissue samples (in triplicate)
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® real-time PCR on an ABI PRISM 7700
Sequence Detection System (Applied Biosystems,
Rotkreuz, Switzerland) as previously described [2]. The
“Candidatus M. turicensis” copy numbers per cell in the
tissue were calculated by dividing the “Candidatus M.
turicensis” copy numbers by the GAPDH copy numbers
[17]. The detection limit of the “Candidatus M. turicensis”
real-time PCR was 200 copies/mL of blood and 66 copies/
10
6 cells.
Serology
Antibodies to “Candidatus M. turicensis” were assessed
in serum samples using an enzyme-linked immunosor-
bent assay (ELISA) and a recombinant DnaK protein as
previously described [18]. We used a serum dilution of
1:100 and 50 ng of the recombinant protein per well.
The signal-to-noise ratio was calculated by dividing the
postinfection absorbance by the preinfection absorbance
values for each individual cat [18]. An ELISA signal-to-
noise ratio of ≥1.5 was considered to be positive [18].
Statistics
Statistical analyses were performed using the Excel add-in
Analyse-it (Analyse-it Software, Leeds, UK), and we used
nonparametric tests. The parameters were compared
between two groups using the Mann-Whitney U-test
(PaMWU). The Wilcoxon signed-rank test (PWilcoxon)w a s
used to compare “Candidatus M. turicensis” antibody
levels from the same cat at two different time points, and
Friedman’st e s t( PFriedman) was used to analyze the para-
meters over time when more than two time points were
considered. Frequencies were compared using the chi-
square test (Pchi
2) and Fisher’s exact test (PFisher). P values
< 0.05 were considered to be significant. All reference
ranges of clinical parameters are given as 5% and 95%
quantiles, which were determined from 58 clinically
healthy cats using the same methods applied in the
current study.
Results
“Candidatus M. turicensis” blood and tissue loads
At the beginning of this project, the blood of all ten cats
was “Candidatus M. turicensis”-negative as determined
by real-time PCR. After methylprednisolone administra-
tion, all of the blood samples tested “Candidatus M.
turicensis”-negative in PCR except one sample collected
from cat S1 (group 1) one week after the end of methyl-
prednisolone administration (at day 20, Table 1). The
“Candidatus M. turicensis” blood load of the latter sam-
ple was low (800 copies/mL of blood, Table 1), which
corresponded to 1 copy/10
7 red blood cells. The blood
samples of all five cats in group 2 remained PCR-nega-
tive throughout the experiment. In the tissue samples, a
sufficient amount of amplifiable DNA and the absence
of significant PCR inhibition were confirmed using
GAPDH real-time PCR. The majority of the tissue sam-
ples were PCR-negative for “Candidatus M. turicensis”
(Table 1). Before methylprednisolone administration,
one cat in group 1 (cat R2) was PCR-positive for
“Candidatus M. turicensis” in the salivary gland. At day
20 (one week after the end of methylprednisolone
administration), the tissue samples of two cats in group
1 were PCR-positive for “Candidatus M. turicensis”:
cat R2 in the salivary gland and cat T1 in the liver
(Table 1). Cat R2, which tested PCR-positive twice,
showed an approximately 40-fold higher “Candidatus
M. turicensis” tissue load in the salivary gland at day 20
compared with the “Candidatus M. turicensis” load
prior to methylprednisolone administration (Table 1).
Overall, three out of the five cats that received methyl-
prednisolone showed an increase in “Candidatus M.
turicensis” tissue or blood loads (Pchi
2 = 0.0384; PFisher =
0.1667). By day 42 (four weeks after the end of the
methylprednisolone administration), however, all of the
cats in group 1 were PCR-negative in all the tissues ana-
lyzed. None of the tissue samples from the control cats
in group 2 tested “Candidatus M. turicensis”-positive by
PCR.
Clinical and laboratory parameters
None of the cats developed anemia throughout the
experiment. Cats in group 1 had lymphocyte counts
below the reference range (1 050-6 000 cells/μL) at differ-
ent time points after they received methylprednisolone:
two cats (S1 and X4) at day 9, one cat (X4) at day 14,
t h r e ec a t s( A 2 ,R 2 ,T 1 )a td a y1 6a n do n ec a t( A 2 )a td a y
20. Moreover, the cats in group 1 had significantly lower
lymphocyte counts after the first methylprednisolone
administration compared with the untreated control cats
in group 2 (PMWU < 0.05; Figure 1A); the counts
remained significantly lower until day 70 (Figure 1A). In
addition, the cats in group 1 had significantly higher
blood glucose levels compared with the cats in group 2
(PMWU < 0.05). This difference began after the first
methylprednisolone administration and was observed at
almost all collection time points (the exceptions were
days 2, 11, and 36) (Figure 1B). There were no significant
differences between the two groups of cats in erythrocyte
counts, total leukocyte counts, hematocrit, body tempera-
ture or weight.
Humoral immune response
All cats were seropositive at the start of the study
(ELISA signal-to-noise ratio ≥1.5). Six cats had high
antibody levels (ELISA signal-to-noise ratio >6), three
cats had intermediate levels (ELISA signal-to-noise ratio
between 2 and 4) and one cat had low antibody levels
(ELISA signal-to-noise ratio <2) (Figure 2). There was
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groups 1 and 2 at the beginning of the present study.
A significant decrease in antibody levels (PFriedman=
0.0018) was observed throughout methylprednisolone
administration (from day 0 to 16) in group 1. This
decrease was followed by a significant increase (from
day 16 to 35, PFriedman = 0.0452), which returned the
antibody levels to approximately pretreatment levels
(Figure 2A). In the untreated control group, no signifi-
cant changes in the antibody levels were found during
these periods (Figure 2B). Moreover, no significant
differences in the antibody levels were observed between
groups 1 and 2 at any of the time points tested (17 blood
Table 1 CMt TaqMan
® real-time PCR results of blood and tissue samples collected prior to and after the
methylprednisolone administrations
Group Cat Before MPA
a
(day -14)
1 week after end MPA
(day 20)
4 weeks after end MPA
(day 42)
1A 2 -
b --
R2 +
c salivary gland (264
d) + salivary gland (10 250
d)
+ liver (236
d)
-
S1 - + blood (800
e)-
T1 - + liver (838
d)-
X4 - - -
2A 1 - - -
R1 - - -
S2 - - -
T2 - - -
X5 - - -
a MPA = methylprednisolone administrations;
b - = all samples tested PCR-negative;
c + = at least one PCR-positive result; the positive tissues are listed;
d tissue
loads: copies/10
6 cells;
e blood loads: copies/mL of blood.
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Figure 1 Lymphocyte counts (A) and blood glucose levels (B)
of cats in groups 1 and 2. Values are depicted as mean +/-
standard deviation. Black arrows = methylprednisolone
administration. Cats in group 1 received the methylprednisolone
administrations; cats in group 2 served as untreated control animals.
A) Cats in group 1 had significantly lower lymphocyte counts than
cats in group 2 (pMWU < 0.05) starting after the first
methylprednisolone administration until day 70. B) Cats in group 1
had significantly higher blood glucose levels than cats in group 2
(pMWU < 0.05) starting after the first methylprednisolone
administration at all collection time points with the exceptions of
days 2, 11, and 36.
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Figure 2 Antibody levels to DnaK depicted as ELISA signal-to-
noise ratio. A) Cats in group 1; methylprednisolone administration
(black arrows); B) cats in the untreated control group 2.
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a trend towards difference was found at day 20 when the
cats in group 1 had slightly lower antibody levels than
the cats in group 2 (PMWU = 0.0952). In addition, when
the antibody levels from all ten cats were compared
between day 0 and the end of the project (day 154), we
f o u n dat r e n dt o w a r dad e c r e a s e( PWilcoxon = 0.0840). In
contrast, in cat S1, which was the only cat that was tran-
siently blood PCR-positive, we found an increase in the
antibody levels from day 35 until the end of the experi-
ment, and the antibody level was higher at the end of the
experiment than it was at the beginning.
Discussion
The present study was the first to investigate the
chronic phase of experimental “Candidatus M. turicen-
sis” infection. We documented the detection of “Candi-
datus M. turicensis” in tissues in the absence of
detectable “Candidatus M. turicensis” bacteremia and
demonstrated the persistence of antibodies to “Candida-
tus M. turicensis” many months after exposure. In addi-
tion, attempted immunosuppression did not lead to a
significant reactivation of the infection under the condi-
tions chosen.
Recently, Tasker et al. analyzed blood and tissue copy
number distribution during experimental M. haemofelis
infection [11]. Tissue sequestration was mainly investi-
gated to explain the marked variation in blood copy num-
bers (4 log difference over 2 or 3 days) that can be
observed during M. haemofelis infection. The Tasker et al.
study failed to demonstrate significant tissue sequestration
of M. haemofelis at the time points investigated [11].
Studies have shown that the “Candidatus M. turicensis”
loads do not fluctuate very much in blood and “Candidatus
M. turicensis” blood loads have been shown to decrease
below the PCR detection level earlier than M. haemofelis
blood loads [2,3]. At the beginning of the present study
(12 to 17 months post-”Candidatus M. turicensis” inocula-
tion), the blood from all ten cats tested PCR-negative for
“Candidatus M. turicensis”; thus, no significant contribu-
tion of the “Candidatus M. turicensis” blood loads to tissue
loads was expected. In the present study the tissue samples
were collected using fine needle aspiration (FNA); it has
been demonstrated that material collected by FNA is
appropriate for the detection of various other infectious
pathogens by PCR [19-22] and PCR from specimens
collected by FNA may be more sensitive than PCR from
blood [21] or other detection methods [22]. The presence
of sufficient material (amplifiable DNA) was confirmed for
all FNA samples by feline GAPDH PCR. The detection of
“Candidatus M. turicensis” in the liver and salivary gland
indicated that “Candidatus M. turicensis” was still present
in these cats more than one year after exposure. Currently,
there is no in vitro test system to assess the viability of
hemoplasmas. PCR-positive results do not provide infor-
mation regarding the presence of viable organisms; how-
ever, it is generally believed that the DNA of dead
organisms is immediately cleared from the body [9]. There-
fore, the ~40-fold increase in “Candidatus M. turicensis”
copies in the salivary gland of cat R2, combined with the
PCR-positive results of a tissue sample and a blood sample
from two additional cats (cat S1 and T1) after methylpred-
nisolone administration, supports the hypothesis that there
were still viable organisms in these cats.
The “Candidatus M. turicensis” tissue loads appeared
to be indirectly associated with the elapsed time since
infection. The cats examined in the present study also
underwent a preliminary tissue collection 6 to 11 months
after “Candidatus M. turicensis” infection. At that time,
“Candidatus M. turicensis” was present in three (cats R2,
T1 and X4) of the ten cats (one kidney, two liver and two
bone marrow samples tested positive; data not shown).
A tt h eb e g i n n i n go ft h ep r e s e n ts t u d ya n dp r i o rt o
methylprednisolone administration (12 to 17 months
after the “Candidatus M. turicensis” infection), only one
tissue of one cat was PCR-positive, and, at the end of this
project (18 to 23 months after infection), all the animals
showed negative PCR results in all tissue samples.
Currently, PCR analysis is the method of choice to
diagnose hemoplasma infections. During the chronic
phase of the infection, however, the hemoplasmas are
present at very low levels in the blood and tissues. Thus,
the detection of hemoplasmas in chronically infected
cats is problematic because the bacterial loads are at, or
below, the detection limit of real-time PCR. Therefore, a
PCR-negative result cannot rule out a low-level infec-
tion. The recently developed ELISAs [18,23] offer the
possibility to monitor and quantify the humoral immune
response during chronic “Candidatus M. turicensis”
infection. Because all of the cats in the present study
showed persistently high antibody levels throughout the
entire experiment, complete tissue clearance of the
organisms seemed unlikely. The constant presence of
the antigen may continuously stimulate the immune sys-
tem, which in turn keeps the bacterial copy numbers at
very low levels. Indeed, after methylprednisolone admin-
istration, we found a significant decrease in the antibody
levels, which was associated with an increase in the
number of detectable “Candidatus M. turicensis” copy
numbers as determined by PCR.
The reactivation of feline hemoplasma infection by
corticosteroid administration has been attempted in
M. haemofelis-infected cats treated with antibiotics [6-8],
but these studies did not have a long period between
infection and the attempted reactivation. Although anti-
biotics were effective at reducing M. haemofelis blood
loads, they did not completely eliminate the bacteria and
a reactivation of M. haemofelis infection could be
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to induce relapses of hemoplasmosis in M. haemofelis-
infected cats using splenectomy and glucocorticoid
administration [24]. The authors observed moderate and
irregular bacteremia, which was determined by cytologi-
cal examination, but they did not observe any clinical
s i g n s[ 2 4 ] .T h ep r e s e n ts t u d yw a st h ef i r s tt or e p o r tt h e
attempted reactivation of “Candidatus M. turicensis”
infection. We chose a methylprednisolone dose that has
been successfully used to reactivate feline leukemia virus
(FeLV) infection in cats and was reported to inhibit lym-
phocyte blastogenesis in adult cats [25]. Indeed, the cats
that received methylprednisolone in the present study
demonstrated significantly lower lymphocyte counts in
the peripheral blood compared with the control cats.
Thus, we assumed that the dose of methylprednisolone
used in the present study was sufficient to induce transi-
ent immune suppression in the cats. We were unable to
demonstrate significant reactivation of the “Candidatus
M. turicensis” infection in the present study, which may
have been due to the duration of the infection. Reactiva-
tion might have been more successful at an earlier time
point when more cats were still tissue PCR-positive.
Alternatively, differences in infection kinetics between
M. haemofelis and “Candidatus M. turicensis” may play a
role and immunosuppression may not lead to the reacti-
vation of “Candidatus M. turicensis” infection.
Corticosteroid therapy has been reported to affect
humoral immunity. In particular, corticosteroids may
reversibly decrease B cell counts and specific antibody
responses [26,27]. Similarly, the cats in group 1 of the
present study showed a significant decrease in their anti-
body levels immediately after methylprednisolone
administration, however, the reduction was transient. To
the best of our knowledge, this was the first study to
show under well-controlled conditions the effect of
methylprednisolone on the antibody levels of cats.
In conclusion, the results of the present study contribute
to the understanding of the pathogenesis of “Candidatus
M. turicensis” infection. Although chronically infected cats
recovered from bacteremia, we demonstrated that “Candi-
datus M. turicensis” remained detectable by PCR in tissues
at low levels for many months. In addition, antibodies to
“Candidatus M. turicensis” remained at high levels in at
least some of the cats throughout the entire monitoring
period. The attempted immunosuppression did not lead to
a significant recurrence of bacteremia and disease at this
stage of infection. Thus, chronically “Candidatus M. turi-
censis” infected cats do not appear to be a major source of
infection for other cats.
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